Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Deals Drug

United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug

Fineline Cube Mar 25, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...

Company Deals

Fapon Biotech Partners with Tencent Healthcare to Boost IVD and Medical Device Fields

Fineline Cube Mar 25, 2025

China-based biotech Fapon Biotech Inc. has formed a strategic partnership with Tencent Healthcare, the healthcare...

Company Drug

Joint Biosciences’ OVV-01 Receives FDA Fast Track Designation for Soft Tissue Sarcoma Trial

Fineline Cube Mar 25, 2025

Shanghai-based Joint Biosciences Ltd., a developer of tumor combined immunotherapies, has announced receiving fast track...

Company Drug

Sino Biopharmaceutical’s Culmerciclib Shows Positive Results in Phase III Breast Cancer Trial

Fineline Cube Mar 25, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has revealed positive results from the Phase III TQB3616-III-02...

Company Drug

Humanwell Healthcare Receives NMPA Approval for Caplyta Generic in Schizophrenia Trial

Fineline Cube Mar 25, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced receiving clinical trial approval from...

Company

Clover Biopharmaceuticals Receives Termination Notice from GAVI for COVID-19 Vaccine Agreement

Fineline Cube Mar 25, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced receiving a one-month prior written notice dated March...

Company

Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift

Fineline Cube Mar 25, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) has released its 2024 financial performance report, recording RMB...

Company

Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales

Fineline Cube Mar 25, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of...

Company

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals

Fineline Cube Mar 25, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...

Drug Medical Device Policy / Regulatory

China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement

Fineline Cube Mar 25, 2025

China’s National Healthcare Security Administration (NHSA) has released its 2024 “Healthcare Security Development Statistical Bulletin.”...

Company Medical Device

Jenscare Scientific’s Ken Valve Receives NMPA Marketing Approval

Fineline Cube Mar 25, 2025

Jenscare Scientific Co., Ltd (HKG: 9877), a Ningbo-based structural heart disease device maker, has announced...

Company Drug

SineuGene Therapeutics’ SNUG01 Receives FDA Clearance for ALS Clinical Study

Fineline Cube Mar 25, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced last week that...

Company Drug

GSK’s Nucala Accepted for EMA Review for COPD Treatment

Fineline Cube Mar 25, 2025

UK-based GSK plc’s (LON: GSK, NYSE: GSK) application for expanding the use of its anti-interleukin-15...

Company Deals

Opella and JD Healthcare Collaborate to Enhance Fatty Liver Awareness in China

Fineline Cube Mar 25, 2025

Opella, the consumer health business of French giant Sanofi (EPA: SAN, NASDAQ: SNY), held a...

Company Deals

Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million

Fineline Cube Mar 25, 2025

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil...

Company Drug

Shanghai Ark Biopharmaceutical’s AK0901 Meets Phase III Endpoints in ADHD Trial

Fineline Cube Mar 25, 2025

China’s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study...

Company

WuXi XDC Reports 90.8% Revenue Surge, Expanding in ADC Market

Fineline Cube Mar 25, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...

Company Drug

Suzhou Xueji Biotech’s XJ-MK-002 Gets FDA Orphan Drug Designation for CAMT

Fineline Cube Mar 25, 2025

China-based cell therapy developer Suzhou Xueji Biotechnology Co., Ltd’s (HemaCell) XJ-MK-002, described as the world’s...

Company Drug

Beijing Sungen Biomedical’s SGC001 Receives FDA Fast Track Designation for AMI Treatment

Fineline Cube Mar 25, 2025

China-based Beijing Sungen Biomedical Technology Co., Ltd, an antibody developer incubated by Hotgen Biotech Co.,...

Company Deals

CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China

Fineline Cube Mar 25, 2025

Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an...

Posts pagination

1 … 233 234 235 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.